NEO100 Research Shows Impact On Recurrent Grade 4 Astrocytoma

by NeOnc | Mar 17, 2025

Main > NEO100 NEO100 Research  |  March 17, 2025 > NEO100 Research Shows Impact On Recurrent Grade 4 Astrocytoma Patients with grade 4 gliomas, particularly those experiencing recurrence, need better treatment options. Researchers are developing NEO100, a...

NEO100 Intranasal Delivery Technology Shows Promise for Better Therapeutic Results.

by NeOnc | Feb 14, 2025

Main > NEO100 NEO100 Research  |  February 12, 2025 > NEO100 Intranasal Delivery Technology Shows Promise for Better Therapeutic Results. This paper discusses the need for better treatment options for patients suffering from astrocytoma and glioblastoma (GBM),...

NEO100 Enhances Entry And Therapeutic Activity Of Chimeric Antigen Receptor T Cells

by NeOnc Technologies | Dec 29, 2023

Main > NEO100 NEO100 Research  |  December 29, 2023 > NEO100 Enhances Entry And Therapeutic Activity Of Chimeric Antigen Receptor T Cells In an article published in the Journal of Neurosurgery website, the study results were posted on Neonc Technologies...

Transfemoral Injection of NEO100 Provides Potential for Delivery of Therapeutics to the Brain

by NeOnc Technologies | May 4, 2023

Main > NEO100 NEO100 Research  |  May 4, 2023 > Transfemoral Injection of NEO100 Provides Potential for Delivery of Therapeutics to the Brain In an article published on the Oncotarget.com website, the use of transfemoral injection of NEO100 to provide entry for...

Postsurgical Biopsy Shows Viability of NEO100 Intranasal Delivery

by NeOnc Technologies | Aug 22, 2022

Main > NEO100 NEO100 Research  |  AUGUST 22, 2022 > Postsurgical Biopsy Shows Viability of NEO100 Intranasal Delivery In a recent case trial follow up of a patient with a recurring glioblastoma (GBM) tumor who had been undergoing NEO100 intranasal treatment, a...